Indian pharmaceutical company Zydus Cadila has signed a strategic collaboration agreement with Turkish-based healthcare company Eczacibasi Ilaç Pazarlama, in a bid to commercialise biotech products in the Turkish market.
Under the agreement, the companies will import biosimilars that are at present unavailable in Turkey, especially for the treatment of cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The deal also helps develop a long-term strategic collaboration with an aim to manufacture and launch new products in the country’s market.
Zydus Group chairman and managing director Pankaj Patel said: “We are glad to partner with Eczacibasi, a leading group in the field of healthcare in Turkey, to make available biotech therapies for patients in Turkey.
“The long-term agreement between both partners to enrich this collaboration through introduction of new products will augur well for healthcare access beyond geographies.”
Eczacibasi chairman Bülent Eczacibasi said that the company believes the new collaboration will not only facilitate innovation but will also create added value in the field of healthcare.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBülent Eczacibasi said: “Our target is to ensure that the important worldwide advances in the field of biotech products are simultaneously reflected and reach more people in our country, and think that Zydus is a very right partner in this regard.”
Headquartered in Ahmedabad, India, Zydus Cadila discovers and manufactures, as well as markets a wide range of healthcare therapies.
Zydus Cadila is currently marketing eight biosimilars products in India and aims at increasing patients’ access to high-quality biosimilars at affordable costs.
